Qiagen N.V. (NYSE:QGEN) Increases Dividend to $0.35 Per Share

Qiagen N.V. (NYSE:QGEN) declared an annual dividend on Monday, May 11th. Shareholders of record on Tuesday, July 7th will be given a dividend of 0.35 per share on Tuesday, July 14th. This represents a yield of 104.0%. The ex-dividend date is Tuesday, July 7th. This is a 33.0% increase from Qiagen’s previous annual dividend of $0.26.

Qiagen has a payout ratio of 10.3% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Qiagen to earn $2.69 per share next year, which means the company should continue to be able to cover its $0.26 annual dividend with an expected future payout ratio of 9.7%.

Qiagen Trading Up 3.2%

QGEN opened at $33.67 on Wednesday. The business has a 50 day simple moving average of $39.97 and a two-hundred day simple moving average of $46.00. The firm has a market capitalization of $6.94 billion, a price-to-earnings ratio of 17.58, a PEG ratio of 3.25 and a beta of 0.64. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 3.31. Qiagen has a one year low of $32.60 and a one year high of $57.81.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.54 EPS for the quarter, meeting analysts’ consensus estimates of $0.54. The business had revenue of $492.32 million during the quarter, compared to analyst estimates of $496.15 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same quarter in the prior year, the company posted $0.56 EPS. Analysts predict that Qiagen will post 2.43 EPS for the current year.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.